Cortice Biosciences, Inc.   Report issue

For profit Phase 2
Founded: New York NY United States (2008)
Status: Defunct (2019)

Organization Overview

First Clinical Trial
2008
NCT00113724
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Brain Neoplasms (Phase 2)

Breast Neoplasms (Phase 2)

Central Nervous System Neoplasms (Phase 2)

Glioblastoma (Phase 2)

Hodgkin Disease (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Medulloblastoma (Phase 2)

Melanoma (Phase 2)

Neoplasms (Phase 2)

Nervous System Neoplasms (Phase 2)

Neuroblastoma (Phase 2)

Pancreatic Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 14
  • # of Trial APIs: 7